Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an ...
Medscape

Meningioma Warning Added to Depo-Provera Label

The action follows mounting scientific evidence linking the injectable contraceptive medication to an increased risk for meningioma.
Pharmabiz

US FDA grants 510(k) marketing clearance to Zephyrus Innovations’ VaporShield CSTD

US FDA grants 510(k) marketing clearance to Zephyrus Innovations’ VaporShield CSTD: Vancouver, BC Wednesday, December 17, 2025, 14:00 Hrs [IST] Zephyrus Innovations (Zephyrus), ...
TipRanks on MSN

Invivyd earns Fast Track designation for VYD2311

Invivyd (IVVD) announced that the U.S. Food and Drug Administration has granted Fast Track designation for VYD2311, an investigational ...
Investing.com Canada

Invivyd stock rises after FDA grants Fast Track designation for COVID antibody

Invivyd shares rose about 2.4% in premarket trading after the company announced that the U.S. Food and Drug Administration has granted Fast Track designation for ...

MannKind Shares FUROSCIX Business Updates

FDA approves FUROSCIX- for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 ...
Le Lézard

New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

Indivior PLC today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses ...

Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight management

Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial1Wegovy pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major advers ...
PharmiWeb

European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1The decision is supported by the ...
Nature

Intramuscular Injection Techniques and Sciatic Nerve Injury

Intramuscular injection remains a cornerstone of clinical practice, offering rapid drug absorption and efficacy when performed correctly. However, its success is intrinsically linked to precise ...